R&D rebate is not included in the $3.5m of cash receipts from customers as the ATO is not a customer. It is included in 2.1(e) - intellectual property as a net amount of the R&D rebate less the R&D spend for the quarter.
Also, the Limepay $200k cash on hand as at acquisition was included in the Sept 4C and is also not included in receipts from customers.
From my reading of the 4C and annualising the R&D rebate across the year, it appears that the operating deficit has reduced to circa $900k per 1/4 based on the December numbers. Therefore an increase in gross cash receipts of a further $2m per quarter should see the gap closed taking into account likely additional costs of that revenue (i.e. revenue split on payments to card schemes etc).
- Forums
- ASX - By Stock
- SPX
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
SPX
spenda limited
Add to My Watchlist
21.4%
!
0.6¢

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-204
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.6¢ |
Change
-0.002(21.4%) |
Mkt cap ! $25.38M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.5¢ | $11.29K | 1.872M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
50 | 26689523 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 336560 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
50 | 26689523 | 0.005 |
8 | 15700000 | 0.004 |
8 | 25200000 | 0.003 |
3 | 4500001 | 0.002 |
4 | 8990002 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 336560 | 4 |
0.007 | 17197256 | 21 |
0.008 | 5622738 | 28 |
0.009 | 11710538 | 17 |
0.010 | 1346835 | 6 |
Last trade - 15.59pm 26/06/2025 (20 minute delay) ? |
Featured News
SPX (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online